Jana Markova

Jana Markova

Auto-generated profile, based on publicly available information

Jana Markova

Department of Internal Medicine-Hematology, University Hospital Kralovske Vinohrady, Third Faculty of Medicine, Charles University, Prague, Czech Republic

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 January 2018 in Česká a slovenská neurologie a neurochirurgie
Verified
Journal Article
Closed access
JMJana Marková
Jana Marková
MHMichal Hajdúk
Michal Hajdúk
ZKZuzana Kosutzka
Zuzana Kosutzka
AKAlice Kušnírová
Alice Kušnírová
MPMariana Pápayová
Mariana Pápayová
ZCZsolt Cséfalvay
Zsolt Cséfalvay

5 December 2023 in Annals of Oncology
Verified
Journal Article
Open access
Justin FerdinandusJustin Ferdinandus
Justin Ferdinandus
HMH. Müller
H. Müller
CDC. Damaschin
C. Damaschin
AJA.S. Jacob
A.S. Jacob
JMJ. Meissner
J. Meissner
KBK. Behringer
K. Behringer
Persisting cancer-related fatigue impairs health-related quality of life (HRQoL) and social reintegration in patients with Hodgkin's lymphoma (HL). The GHSG HD18 trial established treatment de-escalation for advanced-stage HL guided by positron emission tomography after two cycles (PET-2) as new standard. Here, we investigate the impact of treatment de-escalation on long-term HRQoL, time to recovery from fatigue (TTR-F), and time to return to work (TTR-W). Patients received European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30) and life situation questionnaires at baseline, interim, end of treatment, and yearly follow-up. TTR-F was defined as time from the end of chemotherapy until the first fatigue score <30. TTR-W was analyzed in previously working or studying patients and measured from the end of treatment until the first documented work or education. We compared duration of treatment on TTR-F and TTR-W using Cox proportional hazards regression adjusted for confounding variables. HRQoL questionnaires at baseline were available in 1632 (83.9%) of all randomized patients. Overall, higher baseline fatigue and age were significantly associated with longer TTR-F and TTR-W and male sex with shorter TTR-W. Treatment reduction from eight to four chemotherapy cycles led to a significantly shorter TTR-F [hazard ratio (HR) 1.41, P = 0.008] and descriptively shorter TTR-W (HR 1.24, P = 0.084) in PET-2-negative patients. Reduction from six to four cycles led to non-significant but plausible intermediate accelerations. The addition of rituximab caused significantly slower TTR-F (HR 0.70, P = 0.0163) and TTR-W (HR 0.64, P = 0.0017) in PET-2-positive patients. HRQoL at baseline and age were the main determinants of 2-year HRQoL. Individualized first-line treatment in patients with advanced-stage HL considerably shortens TTR-F and TTR-W in PET-2-negative patients. Our results support the use of response-adapted shortened treatment duration for patients with HL.

1 March 2015 in Acta Haematologica
Verified
Journal Article
Open access
HMHeidi Mocikova
Heidi Mocikova
RPRobert Pytlik
Robert Pytlik
PSPavla Stepankova
Pavla Stepankova
JMJozef Michalka
Jozef Michalka
JMJana Markova
Jana Markova
ZKZdenek Kral
Zdenek Kral
Background: Nodular lymphocyte-predominant Hodgkin's lymphoma (NLPHL) is a rare subtype of Hodgkin's lymphoma showing strong CD20 expression. The role of rituximab in treating NLPHL still needs clarification. Methods: We retrospectively reviewed the outcome of 23 patients with NLPHL treated with rituximab alone or in combination with chemotherapy and/or radiotherapy as part of their first- or second-line treatment. Results: The median follow-up of the whole group was 67 months, and all patients remained alive. Twenty-two patients achieved complete remission after rituximab-based therapy, and one of them relapsed 32 months after treatment. One patient treated with rituximab alone achieved partial remission and progressed 22 months after treatment. Conclusion: The prognosis of NLPHL is excellent. Rituximab combined with chemotherapy and/or radiotherapy appears to prevent disease progression/relapse.

5 November 2021 in Blood
Verified
Journal Article
Open access
HMHeidi Mocikova
Heidi Mocikova
JMJana Markova
Jana Markova
LGLubica Gaherova
Lubica Gaherova
MMMaria Maco
Maria Maco
ASAlice Sykorova
Alice Sykorova
TKTomas Kozak
Tomas Kozak
Introduction. EORTC H10 trial confirmed better selection of patients who needed reduced or more intensive treatment using PET response after 2 cycles of ABVD in early stages of classical Hodgkin lymphoma (cHL). GHSG HD17 showed that radiotherapy can be safely omitted in PET4-negative early unfavorable HL treated with 2 cycles of BEACOPP escalated plus 2 cycles of ABVD (2+2 chemotherapy). We compared PET2-adapted approach including 30Gy involved-node radiotherapy (INRT) with 2+2 chemotherapy followed by 30 Gy INRT (or involved-field radiotherapy, IFRT) regardless of interim PET in patients with early unfavorable cHL assessed according to the GHSG risk factors. Methods. Overall 243 patients with early unfavorable cHL (aged 18-60 years) prospectively observed in the Czech Hodgkin lymphoma study group registry between 2003-2020 were analyzed. Patients in clinical stage IIB with massive mediastinal tumor and/or with extranodal disease were not included into this analysis as they were treated with BEACOPP escalated only. Chemotherapy 2+2+30 Gy INRT/IFRT received 213 patients. Overall 30 patients were treated with PET2-adapted approach: 29 PET2-negative patients received 4 cycles of ABVD and 30 Gy INRT and one PET2-positive patient was treated with 2 cycles of ABVD plus 2 cycles of BEACOPP escalated and 30 Gy INRT. Results. Median age at the time of cHL diagnosis was 32 (range 18-59) years. Median follow-up was longer in the 2+2+INRT/IFRT group (91.3, range 6.2-211.2) months when compared to the PET2-adapted approach (19.4, range 6.4-90.4) months. The estimated 2-year progression-free survival (PFS) did not differ in both groups (100% [95% CI 100-100] both), however, the estimated 5-year PFS was significantly better in the 2+2+INRT/IFRT group (99.5% [95% CI 98.5-100]) in comparison to PET2-adapted treatment (75.0% [95% CI 32.5-100]), p<0.001. The estimated 5-year overall survival was comparable in both groups (2+2+INRT/IFRT: 99.5% [95% CI 98.5-100]; PET2-guided treatment: 100% [95% CI 100-100]). Hematological toxicity was reported in most of the patients in both groups. Grade 3 non-hematological toxicity occured in 3 patients in the 2+2+INRT/IFRT approach (2 infections, 1 deep vein thrombosis). Conclusion. This retrospective analysis indicates that 2+2+INRT/IFRT is more effective in the long-term disease control, but there is no difference in overall survival in both groups. The current approach includes 2+2 chemotherapy and INRT is added in PET4-positive patients. This work was supported by the Research project Q 28 Progres awarded by the Third Faculty of Medicine of Charles University in Prague in the Czech Republic.

15 March 2022 in International Journal of Economics and Statistics
Verified
Journal Article
Open access
RPRastislav Petráš
Rastislav Petráš
JŠJana Šnircová
Jana Šnircová
MHMartina Horváthová
Martina Horváthová
MHMária Homokyová
Mária Homokyová
JMJana Marková
Jana Marková
This paper examines the relationship of tax policy of state and the creation of profit in selected tax subjects. The aim of paper is in the context of more than a decennial development of economy of Slovakia to verify and to the numerical rich material to show whether the tax reform in 2004, which was declared as pro-business oriented by then government, significantly affected the financial results of companies.

12 February 2019 in European Neuropsychopharmacology
Verified
Journal Article
Closed access
MKM. Králová
M. Králová
ĽIĽ. Izáková
Ľ. Izáková
BHB. Mészáros Hideghéty
B. Mészáros Hideghéty
MHM. Hajdúk
M. Hajdúk
JMJ. Marková
J. Marková
ZCZ. Cséfalvay
Z. Cséfalvay